Iovance Biotherapeutics
IOVA
286 hedge funds and large institutions have $2.21B invested in Iovance Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 108 increasing their positions, 84 reducing their positions, and 46 closing their positions.
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
79% more call options, than puts
Call options by funds: $44.1M | Put options by funds: $24.7M
29% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 84
19% more capital invested
Capital invested by funds: $1.86B → $2.21B (+$346M)
3% less funds holding
Funds holding: 295 → 286 (-9)
5.59% less ownership
Funds ownership: 83.1% → 77.51% (-5.6%)
15% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$51.3M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$36.1M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$30.2M |
| 4 |
Goldman Sachs
New York
|
+$16.8M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$14.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$70.7M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
-$22.6M |
| 3 |
JP Morgan Chase
New York
|
-$14.6M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$12.9M |
| 5 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$12.5M |
IOVA Hedge Fund Activity: Q3 2024 in Review
286 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2024, worth a combined $2.21B — up 19% from $1.86B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of IOVA and 39 opened new positions — a net loss of 7 holders — while 84 trimmed existing stakes and 108 added.
The largest buyer was Hood River Capital Management, adding an estimated $51.3M. The largest seller was Avoro Capital Advisors, cutting an estimated $70.7M.
- 286 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2024, down from 295 in Q2 2024.
- Funds reported $2.21B of Iovance Biotherapeutics stock for Q3 2024, up 19% quarter-over-quarter.
- 39 funds opened new Iovance Biotherapeutics positions in Q3 2024 and 46 closed out, a net change of -7 holders.
- The largest Iovance Biotherapeutics buyer in Q3 2024 was Hood River Capital Management, an estimated $51.3M added.
- The largest Iovance Biotherapeutics seller in Q3 2024 was Avoro Capital Advisors, an estimated $70.7M sold.
Based on aggregated 13F filings for Q3 2024.